Local therapy and intrathecal chemotherapy may manage CNS progression in EGFR-mutant NSCLC patients
Combined Treatments May Help Manage Brain Metastases in Lung Cancer
This case report and literature review describes a patient with EGFR-mutant NSCLC and brain/leptomeningeal metastases. The authors suggest t…
A new treatment approach combining surgery, local chemotherapy, and targeted drugs may help manage brain cancer spread for some patients.
Sotorasib resistance linked to transformation to pulmonary giant cell carcinoma in KRAS G12C lung adenocarcinoma
Lung cancer can change form after targeted drug treatment
A case report with literature review describes a 71-year-old man with KRAS G12C-mutant lung adenocarcinoma whose tumor transformed to pulmon…
A man's lung cancer transformed into a more aggressive type after taking the targeted drug sotorasib, highlighting the need for re-biopsy wh…
CT-based deep learning models show high accuracy predicting EGFR mutation status in lung adenocarcinoma
Machine learning models help predict lung cancer mutations from scans
This meta-analysis of 6,628 Chinese patients with lung adenocarcinoma found that machine learning-based radiomics models provide a noninvasi…
New analysis shows that deep learning models can accurately identify specific lung cancer mutations using standard CT scans.
Observational study links ADAM9 expression to survival in lung adenocarcinoma patients
High ADAM9 levels linked to worse lung cancer survival in new data
This research article is an observational study with in vitro experiments analyzing TCGA-LUAD datasets from 517 tumor and 59 normal tissues.…
High ADAM9 expression linked to immunosuppression and poorer survival in lung adenocarcinoma patients based on tissue data and lab experimen…
Case report suggests second primary glioblastoma in ALK-positive lung adenocarcinoma patient treated with ensartinib and lorlatinib
A single patient case warns doctors to check for second cancers when tumors act strangely
This case report describes a 63-year-old female with ALK-positive lung adenocarcinoma who received ensartinib, lorlatinib, and stereotactic …
A 63-year-old woman with lung cancer developed a new brain tumor that was not a metastasis. Doctors must carefully examine unusual tumor gro…
Case report on ivonescimab for EGFR-TKI-resistant lung adenocarcinoma with pericardial effusion
One Drug Shrinks Lung Tumors When Others Stop Working
This is a case report and literature review of a 77-year-old female with EGFR-TKI-resistant advanced lung adenocarcinoma and malignant peric…
A 77-year-old woman with advanced lung cancer saw her tumors shrink and dangerous fluid around her heart disappear after trying a new drug c…
Case report and review highlights ultrasound-guided microwave ablation for metastatic breast cancer in a single patient
Microwave Ablation Controls Breast Metastasis for Three Years
This case report and review of the literature describes ultrasound-guided microwave ablation in a 59-year-old female with metastatic breast …
A single session of microwave ablation kept a breast cancer metastasis under control for three years with no major side effects.
Case Report Details Aumolertinib Rechallenge Following Osimertinib-Induced Interstitial Lung Disease in Lung Adenocarcinoma
Can lung cancer drugs be restarted after severe lung injury?
This case report describes a 73-year-old male with stage IV lung adenocarcinoma and EGFR exon 19 deletions who experienced interstitial lung…
Doctors successfully restarted a powerful lung cancer drug after a patient's lungs healed from a dangerous reaction to the first one.
Case report and literature review on T-SMARCA4-DUT diagnosis and treatment response in a single patient
A Rare Tumor That Fooled Doctors at Every Step — Until One Test Changed Everything
This case report and literature review describes a 64-year-old male with thoracic SMARCA4-deficient undifferentiated tumor initially misdiag…
A rare chest tumor mimicking lung cancer was misdiagnosed until a specific genetic test revealed the true cause, proving one marker can prev…
Review describes Virtual Spectral Decomposition framework for cancer imaging analysis
AI Now Reads Tumor Slides Like a Radiologist — and Shows Its Work
This review/commentary outlines a Virtual Spectral Decomposition (VSD) methodological framework for analyzing digital pathology and imaging …
A new AI system reads cancer slides like a doctor and explains exactly which biological features drove each diagnosis.
Gene expression programs associated with survival and recurrence in early-stage lung adenocarcinoma patients
Why Your Lung Cancer Risk Is Not The Same As Your Neighbor's
This retrospective cohort study evaluated gene expression programs in early-stage (IA/IB) lung adenocarcinoma patients.
Hidden immune signals in early lung cancer act like a weather forecast, predicting who will stay well and who faces a quick return of the di…
NR2F2 expression in CAFs linked to poor prognosis and enhanced tumor progression in lung adenocarcinoma models
A Hidden Cell Type in Lung Cancer May Hold a New Target
This preclinical and computational study analyzed public databases and performed in vitro experiments to evaluate cancer-associated fibrobla…
A hidden protein in support cells around lung tumors may drive cancer growth, pointing to a new treatment target for lung adenocarcinoma.
Research across Extensive-Stage Small-Cell Lung Cancer
Related studies from across the Extensive-Stage Small-Cell Lung Cancer family.
Lower baseline soluble PD-L1 levels correlate with improved progression-free and overall survival in NSCLC
Blood Marker May Predict Lung Cancer Outcomes
This meta-analysis of 1967 patients with non-small cell lung cancer (NSCLC) found that lower baseline sPD-L1 levels are associated with sign…
A protein in the blood called sPD-L1 may help predict how well lung cancer patients respond to treatment.
Evaluating Bevacizumab Addition to Atezolizumab Carboplatin and Pemetrexed in Nonsquamous NSCLC
Trial shows bevacizumab addition has mixed results for lung cancer
A Phase III trial assessed adding bevacizumab to a standard triplet regimen for advanced nonsquamous NSCLC, showing no significant OS improv…
A Phase 3 trial found that adding bevacizumab to a standard drug combination did not improve overall survival for most patients with advance…
Multidisciplinary determination of resectability incorporates tumor biology and perioperative systemic therapy in stage III NSCLC
New Guidelines Redefine Surgery Options for Lung Cancer Patients
This clinical guideline addresses the management of stage III non-small cell lung cancer (NSCLC). It advocates for a multidisciplinary appro…
New guidelines suggest that surgery for certain lung cancers should be based on tumor biology and treatment response rather than just anatom…
Chemoradiotherapy combined with immunotherapy improves progression-free and overall survival in limited-stage small-cell lung cancer
Immunotherapy Combined With Chemoradiotherapy Shows Promise for Lung Cancer
This meta-analysis of randomized controlled trials evaluated the impact of chemoradiotherapy (CCRT) plus immunotherapy on 1,853 patients wit…
Adding immunotherapy to standard chemoradiotherapy shows a favorable trend in survival for patients with limited-stage small-cell lung cance…
Ensartinib improves 24-month disease-free survival to 86.4% in resected ALK-positive NSCLC
New drug shows promise for specific type of lung cancer
This Phase 3 randomized trial of 274 patients with resected, ALK-positive stage IB to IIIB NSCLC found that ensartinib (225 mg once daily) s…
A new medication called ensartinib significantly improved the time patients lived without their lung cancer returning after surgery.
PD-1 inhibitor plus chemotherapy improves progression-free survival and overall survival in driver gene-negative NSCLC
Adding PD-1 inhibitors to chemotherapy improves lung cancer survival
This network meta-analysis of 20 randomized controlled trials evaluated treatments for driver gene-negative non-small cell lung cancer with …
Combining a specific immunotherapy drug with chemotherapy may help patients with certain types of lung cancer and liver spread live longer.
TROP2-targeting ADCs achieve 50.6% ORR in EGFR-mutant NSCLC following tyrosine kinase inhibitor failure
Antibody-drug conjugates show promise for lung cancer after TKI failure
This systematic review and meta-analysis of 1092 patients found that antibody-drug conjugates (ADCs) provide significant clinical benefits f…
New research highlights how specific antibody-drug conjugates may offer better outcomes for patients with certain types of lung cancer.
Primary and acquired resistance to immune checkpoint inhibitors in NSCLC involves antigen presentation and TME remodeling
Understanding why some lung cancer treatments do not work for every patient
This systematic review synthesizes mechanisms of primary and acquired resistance to PD-1/PD-L1 inhibitors in patients with non-small cell lu…
Doctors are studying why certain immune-boosting drugs fail to stop lung cancer growth. New insights help find better ways to treat patients…
Comparative Efficacy of PD-1 and PD-L1 Inhibitors in Advanced Non-Small Cell Lung Cancer
Analysis shows PD-1 inhibitors may outperform PD-L1 for lung cancer
A meta-analysis suggests that PD-1 inhibitors combined with chemotherapy offer superior survival outcomes compared to PD-L1 inhibitors plus …
A large analysis of over 14,000 patients suggests that certain types of immunotherapy combined with chemotherapy may offer better survival r…
Single-cell and spatial omics provide detailed mapping of tumor-immune ecosystems in non-small cell lung cancer
New Mapping Tools May Improve Lung Cancer Treatment Planning
This mini review explores how single-cell RNA sequencing, chromatin profiling, and spatial transcriptomics offer superior resolution for ana…
Advanced mapping techniques are helping researchers identify how lung cancer cells adapt and hide from current treatments to help plan bette…
Nivolumab plus chemotherapy improves pathological complete response in resectable NSCLC with PD-L1 < 1%
Nivolumab plus chemotherapy improves pathological response in certain lung cancers
This network meta-analysis of 1012 patients with resectable non-small cell lung cancer (NSCLC) and PD-L1 expression < 1% found that nivoluma…
A new analysis shows that adding nivolumab to chemotherapy can improve specific cancer responses for patients with low PD-L1 levels.
Aumolertinib Combined with Chemotherapy Improves Progression Free Survival in EGFR Mutated NSCLC
Combination therapy extends progression free survival in lung cancer
Phase 3 trial results show aumolertinib plus chemotherapy significantly extends progression-free survival compared to monotherapy for advanc…
A new trial shows that combining a specific drug with chemotherapy helps patients with advanced lung cancer live longer without their diseas…
Questions about Lung Adenocarcinoma
How does gene expression affect survival in early-stage lung adenocarcinoma?
Gene expression programs involving immune cells, stromal remodeling, and acylation modifications significantly predict survival and recurrence in early-stage lung adenocarcinoma.
Full answer →Can aumolertinib be used again after osimertinib causes lung problems?
Yes, aumolertinib (almonertinib) has been successfully used after osimertinib caused lung problems like interstitial lung disease, based on case reports.
Full answer →All Lung Adenocarcinoma Articles
- Local therapy and intrathecal chemotherapy may manage CNS progression in EGFR-mutant NSCLC patients
- Sotorasib resistance linked to transformation to pulmonary giant cell carcinoma in KRAS G12C lung adenocarcinoma
- CT-based deep learning models show high accuracy predicting EGFR mutation status in lung adenocarcinoma
- Observational study links ADAM9 expression to survival in lung adenocarcinoma patients
- Case report suggests second primary glioblastoma in ALK-positive lung adenocarcinoma patient treated with ensartinib and lorlatinib
- Case report on ivonescimab for EGFR-TKI-resistant lung adenocarcinoma with pericardial effusion
- Case report and review highlights ultrasound-guided microwave ablation for metastatic breast cancer in a single patient
- Case Report Details Aumolertinib Rechallenge Following Osimertinib-Induced Interstitial Lung Disease in Lung Adenocarcinoma
- Review describes Virtual Spectral Decomposition framework for cancer imaging analysis
- Case report and literature review on T-SMARCA4-DUT diagnosis and treatment response in a single patient
- Gene expression programs associated with survival and recurrence in early-stage lung adenocarcinoma patients
- NR2F2 expression in CAFs linked to poor prognosis and enhanced tumor progression in lung adenocarcinoma models
- Phase Ib/II trial of nintedanib plus nivolumab in pretreated NSCLC adenocarcinoma shows 25% 6-month PFS rate
- Predictive nomogram with spectral CT radiomics and deep learning features improves preoperative STAS prediction in surgically resected lung adenocarcinoma
- AM.score predicts lung adenocarcinoma outcomes and immunotherapy response in a cohort of 1,720 patients
- Radiomics-ML model predicts invasiveness in subcentimeter subsolid lung adenocarcinoma
- CT-based radiomics shows variable accuracy for predicting occult lymph node metastasis in early-stage lung adenocarcinoma